Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161858 · ClinicalTrials.gov registry record
Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia
A clinical trial of Primary Ciliary Dyskinesia and Kartagener Syndrome, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 105
- Enrollment target
- 7
- Study locations
NCT05161858: Completed study of Primary Ciliary Dyskinesia and Kartagener Syndrome, sponsored by University of North Carolina, Chapel Hill.
NCT05161858 is a study of Primary Ciliary Dyskinesia and Kartagener Syndrome that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 105 participants, above the 95-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (11% higher). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05161858, a study of Primary Ciliary Dyskinesia and Kartagener Syndrome, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
- 7
- Study locations
Study Summary
The overall objective of this longitudinal, observational study is to provide information needed to inform the design of future interventional trials of respiratory exacerbation prevention and treatment in children and adults with primary ciliary dyskinesia (PCD).
Primary Outcome
Forced expired volume in 1 second (FEV1) will be assessed by percentage of the predicted value (0-100%).
Conditions Studied
Study Locations (7)
California
- Stanford University - Palo Alto
Colorado
- Children's Hospital Colorado - Aurora
Missouri
- Washington University in St. Louis - St Louis
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Washington
- Seattle Children's Hospital - Seattle
Ontario
- The Hospital for Sick Children - Toronto
Quebec
- McGill University - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2022-03-29 |
| Est. Completion | 2025-09-30 |
What the finished NCT05161858 record still lists
NCT05161858 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, above the 95-participant average among 7 other Primary Ciliary Dyskinesia trials with a reported enrollment target (11% higher).
The record links to 2 conditions, with Primary Ciliary Dyskinesia appearing as the primary indexed condition, and to 0 interventions.
NCT05161858 lists 7 locations in 7 states (California, Colorado, Missouri).
Frequently Asked Questions
What is clinical trial NCT05161858 about?
NCT05161858 is a clinical study titled "Longitudinal Characterization of Respiratory Tract Exacerbations and Treatment Responses in Primary Ciliary Dyskinesia". The overall objective of this longitudinal, observational study is to provide information needed to inform the design of future interventional trials of respiratory exacerbation prevention and treatment in children and adults with primary ciliary dyskinesia (PCD).
What is the current status of trial NCT05161858?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2022-03-29. Estimated completion is 2025-09-30.
What conditions does trial NCT05161858 study?
This clinical trial studies the following conditions: Primary Ciliary Dyskinesia, Kartagener Syndrome.
Who is sponsoring clinical trial NCT05161858?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05161858 being conducted?
This trial has 7 study locations across California, Colorado, Missouri, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Ciliary Dyskinesia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Examining Bronchial Hyperresponsiveness in Primary Ciliary Dyskinesia
RECRUITING · NA
-
Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
RECRUITING
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING · NA
-
Utility of PCD Diagnostics to Improve Clinical Care
RECRUITING
-
A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
ACTIVE NOT RECRUITING
-
A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI